ABVC
ABVC BIOPHARMA, INC.
+0.06 (+6.02%)1.15USD145K成交股數30.5M市值–本益比(近四季)103.1股價營收比–營收年增(近四季)–下次財報
財報 SEC XBRL 申報值 · 美元 · 財年於 12 月結束
逐季數字是 10-Q 的單季值;財年第四季 XBRL 只有年度值,這裡用年度減前三季推算。年增率比的是去年同一會計季。
營收與利潤率近 16 季
稀釋 EPS近 16 季 · 美元
現金流近 16 季
股東回饋近 16 季 · 庫藏股與股利
損益表 逐季 · 最新在左 · 小字是年增率
| 科目 | 26Q2 | 26Q1 | 25Q4 | 25Q3 | 25Q2 | 25Q1 | 24Q3 | 24Q2 | 24Q1 | 23Q4 | 23Q3 | 23Q2 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 營收 | – | – | – | 796K+579% | – | – | 389K+2351% | 117K+1818% | 1K | 2K | 16K | 6K |
| 營業成本 | – | – | – | – | – | – | 296.00 | 190.00 | 277.00 | 139K | 30K | 73K |
| 毛利 | – | – | – | 796K+581% | – | – | 389K-2933% | 117K-275% | 928.00 | −137K | −14K | −67K |
| 毛利率 | – | – | – | 100.0% | – | – | 99.9% | 99.8% | 77.0% | -6,329.8% | -86.4% | -1,094.6% |
| 研發費用 | 23K | 33K | 29K | 30K | 33K | 29K | 38K | 40K | 69K | 72K | 141K | 514K |
| 銷售管理費用 | 504K | 752K | 784K | 798K | 690K | 615K | 558K | 654K | 738K | 1.5M | 1.2M | 1.4M |
| 營業利益 | −780K-66% | −1.6M+127% | −2.2M+627% | −2.0M+128% | −2.3M-19% | −693K+35% | −302K-86% | −860K-61% | −2.8M | −512K | −2.2M | −2.2M |
| 營業利益率 | – | – | – | -246.8% | – | – | -77.7% | -734.2% | -235,539.8% | -23,641.3% | -13,566.3% | -35,911.6% |
| 稅後淨利 | −737K-67% | −1.6M+85% | −2.8M+601% | −2.0M+117% | −2.3M-20% | −842K+120% | −395K-88% | −942K-58% | −2.8M | −383K | −3.3M | −2.3M |
| 淨利率 | – | – | – | -256.6% | – | – | -101.4% | -804.4% | -235,203.2% | -17,705.7% | -20,885.9% | -37,052.1% |
| 稀釋 EPS | -0.03-77% | -0.060% | -0.11+267% | -0.09+13% | -0.13-55% | -0.06-124% | -0.03-96% | -0.08-88% | -0.29 | 0.25 | -0.82 | -0.68 |
| 稀釋股數 | 26.1M | 25.4M | 20.1M | 23.3M | 17.4M | 15.0M | 12.4M | 11.3M | 9.7M | 4.3M | 4.1M | 3.3M |
資產負債表 期末餘額
| 科目 | 26Q2 | 26Q1 | 25Q4 | 25Q3 | 25Q2 | 25Q1 | 24Q3 | 24Q2 | 24Q1 | 23Q4 | 23Q3 | 23Q2 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 現金與約當現金 | 32K | 140K | 681K | 192K | 388K | 152K | 137K | 124K | 30K | 60K | 500K | 99K |
| 應收帳款 | – | – | – | – | – | – | 2K | 2K | 2K | 2K | 2K | 12K |
| 存貨 | – | – | – | 11K | 11K | 11K | – | – | – | – | – | – |
| 總資產 | 19.4M | 19.7M | 21.1M | 21.2M | 16.2M | 14.9M | 7.8M | 8.0M | 8.0M | 7.8M | 16.6M | 9.3M |
| 有息負債 | – | – | – | – | – | – | – | – | – | – | – | – |
| 總負債 | 7.1M | 6.9M | 7.8M | 6.7M | 6.8M | 6.9M | 6.4M | 6.5M | 6.5M | 6.5M | 7.5M | 9.7M |
| 股東權益 | 10.3M | 10.8M | 11.1M | 12.1M | 7.0M | 5.4M | 1.6M | 1.8M | 1.7M | 1.6M | 9.1M | −379K |
| 負債比 | 36.8% | 35.0% | 36.9% | 31.7% | 41.6% | 46.5% | 82.8% | 80.9% | 81.7% | 83.9% | 45.4% | 103.9% |
| 淨現金(現金 − 有息負債) | – | – | – | – | – | – | – | – | – | – | – | – |
現金流量表 單季
| 科目 | 26Q2 | 26Q1 | 25Q4 | 25Q3 | 25Q2 | 25Q1 | 24Q3 | 24Q2 | 24Q1 | 23Q4 | 23Q3 | 23Q2 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 營業現金流 | – | −894K+66% | – | – | – | −540K | – | – | −956K | – | – | – |
| 資本支出 | – | – | – | – | – | – | – | – | – | – | – | – |
| 自由現金流 | – | – | – | – | – | – | – | – | – | – | – | – |
| 折舊攤銷 | – | – | – | – | – | – | – | – | – | – | 7K | 7K |
| 買回庫藏股 | – | – | – | – | – | – | – | – | – | – | – | – |
| 現金股利 | – | – | – | – | – | – | – | – | – | – | – | – |
| 自由現金流率 | – | – | – | – | – | – | – | – | – | – | – | – |
營收拆解
這家公司的 XBRL 沒有標分部、產品或地區營收。多半是單一業務,或只在 10-K 文字裡揭露。
各維度的加總不一定等於合併營收:分部有時含內部交易、地區有時只揭露主要國家。挑的是加總最接近合併營收的那個標籤。
年度 10-K
| 財年 | 營收 | 年增 | 稅後淨利 | 淨利率 | 稀釋 EPS | 自由現金流 |
|---|---|---|---|---|---|---|
| FY2025 | 296K | -41.9% | −7.9M | -2,671.8% | -0.39 | – |
| FY2024 | 510K | +234.3% | −4.9M | -962.1% | -0.42 | – |
| FY2023 | 152K | -84.3% | −7.8M | -5,109.3% | -1.80 | −4.2M |
| FY2022 | 970K | +172.6% | −16.4M | -1,693.5% | -5.19 | −7.5M |
| FY2021 | 356K | -26.3% | −12.8M | -3,608.5% | -0.51 | −7.6M |
| FY2020 | 483K | -31.2% | −10.6M | -2,193.1% | -0.50 | – |
| FY2019 | 702K | +9988.0% | −3.9M | -560.5% | -0.21 | – |
| FY2018 | 7K | – | −6.1M | -87,184.2% | -0.02 | – |